Form 4: Mirum Pharmaceuticals Director Laura Brege Boosts Stake with New Equity Awards

Mirum Pharmaceuticals, Inc. Director Laura Brege reported the acquisition of 5,703 shares of common stock through RSU conversion, along with new grants of 6,268 stock options and 3,977 deferred stock units, increasing her beneficial ownership.

Summary

• Laura Brege, a Director at Mirum Pharmaceuticals, Inc. (MIRM), reported transactions on May 29, 2025.
• She acquired 5,703 shares of common stock through the conversion of restricted stock units (RSUs).
• Following this transaction, her direct beneficial ownership of common stock increased to 15,703 shares.
• Additionally, Ms. Brege was granted 6,268 stock options with an exercise price of $44, expiring on May 28, 2035.
• She also received a grant of 3,977 deferred stock units (DSUs).
• Both the newly granted stock options and deferred stock units have a vesting schedule tied to the first anniversary of the grant date or the Issuer's 2026 annual stockholder meeting.
• The RSUs that converted to common stock were set to vest on the first anniversary of their grant date or the Issuer's 2025 annual stockholder meeting.
• Vested deferred stock units will be paid out in common stock upon a change in control of the Issuer or within 60 days following separation from service.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director increasing their stake and receiving new equity awards, aligning their interests with shareholders, which is generally viewed favorably. It's a routine compensation event but still a positive signal of insider confidence.

Positives

• The acquisition of common stock and the grant of additional equity awards to a director indicate continued alignment of management's interests with shareholders.
• The increase in beneficial ownership by a director can be viewed as a positive signal of confidence in the company's future prospects.

Future Outlook

The document details future vesting schedules for equity awards, with restricted stock units vesting by the 2025 annual stockholder meeting and stock options and deferred stock units vesting by the 2026 annual stockholder meeting or the first anniversary of their grant date. Deferred stock units will be paid out upon a change in control or separation from service.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the pharmaceutical industry, aiming to incentivize long-term commitment and align leadership interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs), Stock Options, and Deferred Stock Units (DSUs) as part of director compensation is a common practice across the biotechnology and pharmaceutical sectors, aligning with typical executive and board compensation structures.
• The vesting schedules (one-year anniversary or next annual meeting) are standard for such equity grants, comparable to practices at companies like Vertex Pharmaceuticals (VRTX) or Gilead Sciences (GILD) for their non-employee directors.

Related Party Transactions

• The reported transactions involve a director of Mirum Pharmaceuticals, Inc. acquiring company securities, which constitutes a related party transaction under SEC regulations.

Stakeholder Impact

• Shareholders: The increase in director ownership aligns management's interests with shareholder value, potentially fostering greater confidence.
• Employees: The equity compensation structure for directors may reflect broader compensation philosophies within the company, potentially influencing employee incentive programs.

Next Steps

• Vesting of restricted stock units on the first anniversary of the grant date or the Issuer's 2025 annual stockholder meeting.
• Vesting of stock options on the first anniversary of the grant date or the Issuer's 2026 annual stockholder meeting.
• Vesting of deferred stock units on the first anniversary of the grant date or the Issuer's 2026 annual stockholder meeting.
• Payout of vested deferred stock units upon a change in control of the Issuer or within 60 days following separation from service.

Key Dates

Recommendation

Keywords

Mirum Pharmaceuticals, MIRM, SEC Form 4, Insider Transaction, Director Stock Ownership, Restricted Stock Units, Stock Options, Deferred Stock Units, Equity Compensation, Beneficial Ownership